CN105315332A - CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof - Google Patents

CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof Download PDF

Info

Publication number
CN105315332A
CN105315332A CN201410312102.7A CN201410312102A CN105315332A CN 105315332 A CN105315332 A CN 105315332A CN 201410312102 A CN201410312102 A CN 201410312102A CN 105315332 A CN105315332 A CN 105315332A
Authority
CN
China
Prior art keywords
ethyl
decahydro
indoles
pyrroles
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410312102.7A
Other languages
Chinese (zh)
Inventor
彭师奇
赵明
王玉记
吴建辉
杜凤翔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Medical University
Original Assignee
Capital Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Medical University filed Critical Capital Medical University
Priority to CN201410312102.7A priority Critical patent/CN105315332A/en
Publication of CN105315332A publication Critical patent/CN105315332A/en
Pending legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses (5aS,12S,14aS)-5,14-dione-12-(2-tryptophanyl amino acid benzyl ester-ethyl-1-yl)-1,2,3,5,5a,6,11,12,14,14a-decahydro-5H,14H-pyrrole[1,2:4,5]-pyrazino[1,2:1,6]pyridino[3,4-b]indole, and a preparation method, a nano structure and an anti-tumor effect thereof, and discloses applications of the compound in medicine.

Description

CIPPC-AA-OBzl, its preparation, nanostructure, active and application
Technical field
The present invention relates to (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5]-pyrazine also [1,2:1,6] pyrido [3,4-b] indoles (being called for short CIPPC-AA-OBzl).Relate to their preparation method, relate to their nanostructure, relate to their antitumor action, illustrate their application in medical science.The invention belongs to biomedicine field.
Technical background
Biological nano system can be observed intuitively.The progress of nanotechnology decades is in the past mainly reflected in delivery system, as liposome.Contriver is devoted to the small molecules nanostructure developed, and is the invention being totally independent of delivery system.
It is one of conditioning agent main in fibrinolytic system that the urokinase type plasminogen activator (uPA) that plasminogen activation (PA) system comprises is not only, and closely related with tumour.In a lot of malignant tumour, the overexpression of uPA can make tumor progression.Lower the potential strategy that uPA has become cancer therapy and prophylaxis of tumours transfer.But not corresponding invention is seen in document at present.
The health of the malignant tumour serious threat mankind.Except self is severe to the prognosis of tumour patient, the transfer of Complicated by Malignancy worsens the prognosis of patient further.Such as, the malignant tumor patient more than more than 90% is all die from metastases.
Contriver once openly descended (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophane base-ethyl-1-base)-1 of structure, 2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5]-pyrazine also [1,2:1,6] pyrido [3,4-b] indoles (being called for short CIPPC) can suppress the plasmin activity of urokinase effectively, display anastalsis.The invention but never suppressing the anastalsis of urokinase plasmin activity to be converted into antitumor action CIPPC is seen in document.
Contriver is in the analysis structure of hundreds of compound and the basis of activity change, recognize that (AA is selected from L-Trp by AA-OBzl, L-Phe, L-Ser, L-Tyr, Lys (Z), L-Pro, L-Leu, L-Ile, L-Val and Gly residue) guide on the carboxyl of the tryptophan residue of CIPPC, CIPPC can be suppressed the anastalsis of urokinase plasmin activity be converted into antitumor action.Based on this understanding, inventors herein propose the present invention.
Summary of the invention
First content of the present invention is to provide (5aS, 12S, the 14aS)-5 of structure below, 14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5]-pyrazine is [1,2:1,6] pyrido [3 also, 4-b] indoles (being called for short CIPPC-AA-OBzl), AA is selected from L-Trp, L-Phe, L-Ser, L-Tyr, Lys (Z), L-Pro, L-Leu, L-Ile, L-Val and Gly residue.
Second content of the present invention is to provide preparation (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5]-pyrazine also [1,2:1,6] method of pyrido [3,4-b] indoles, the method is made up of following steps:
(1) in presence of hydrochloric acid, L-Trp methyl esters and the condensation of 1,1,3,3-tetramethoxy propane are 1-(2,2-dimethoxy-ethyl)-1,2,3,4-Tetrahydrocarboline-3-carboxylate methyl ester;
(2) 1-(2,2-dimethoxy-ethyl)-1,2,3 under diisopropylamine exists, 4-Tetrahydrocarboline-3-carboxylate methyl ester and Z-Pro-Cl condensation are (5aS, 12S/R, 14aS)-5,14-diketone-12-Methylal(dimethoxymethane)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-b] indoles (2);
(3) under the existence of triethylamine and anhydrous sodium sulphate, (5aS, 12S/R, 14aS)-5, 14-diketone-12-Methylal(dimethoxymethane)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles [1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-b] indoles (2) and HClTrp-OBzl condensation be (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-N-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3a) and (5aS, 12R, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-N-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3b),
(4) under ice bath in methyl alcohol (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-N-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3a) hydrolysis generation (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophane ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (CIPPC),
(5) under ice bath in dry DMF, by N, N-dicyclohexylcarbodiimide (DCC) and anhydrous Na 2sO 4make dewatering agent.(5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophane ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (CIPPC) and AA-OBzl N-methylmorpholine reconcile pH to 9, at room temperature coupling generates (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (CIPPC-AA-OBzl).
3rd content of the present invention is mensuration (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B] indoles (CIPPC-AA-OBzl) is to the restraining effect of tumor cell proliferation.
4th content of the present invention is mensuration (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B] indoles (CIPPC-AA-OBzl) is to the restraining effect of tumor growth.
5th content of the present invention is mensuration (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] nanostructure of pyrido [3,4-B] indoles (CIPPC-AA-OBzl).
Accompanying drawing explanation
Fig. 1. (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] the synthetic route .i of pyrido [3,4-B] indoles (CIPPC-AA-OBzl)) hydrochloric acid; Ii) diisopropylamine, Z-Pro-Cl; Iii) triethylamine, anhydrous sodium sulphate and HClAA-OBzl (AA is selected from L-Trp, L-Phe, L-Ser, L-Tyr, Lys (Z), L-Pro, L-Leu, L-Ile, L-Val and Gly residue); Iv) ice bath, methyl alcohol, dry DMF, N, N-dicyclohexylcarbodiimide (DCC), anhydrous Na 2sO 4and N-methylmorpholine.In 4a, AA is L-Trp residue; In 4b, AA is L-Phe residue; In 4c, AA is L-Ser residue; In 4d, AA is L-Tyr residue; In 4e, AA is Lys (Z), residue; In 4f, AA is L-Pro residue; In 4g, AA is L-Leu residue; In 4h, AA is L-Ile residue; In 4i, AA is Gly residue.
Fig. 2. (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] (in 4a, AA is L-Trp residue to pyrido [3,4-B] indoles; In 4b, AA is L-Phe residue; In 4c, AA is L-Ser residue; In 4d, AA is L-Tyr residue; In 4e, AA is Lys (Z), residue; In 4f, AA is L-Pro residue; In 4g, AA is L-Leu residue; In 4h, AA is L-Ile residue; In 4i, AA is Gly residue) 1 × 10 -10transmission electron microscope photo under M concentration.
Embodiment
In order to set forth the present invention further, provide a series of embodiment below.These embodiments are illustrative completely, and they are only used for being specifically described the present invention, not should be understood to limitation of the present invention.
Embodiment 1 prepares (3S)-1-(2,2-dimethoxy ethyl)-2,3,4,9-tetrahydro-beta-carboline carboxylate methyl ester (1)
Be dissolved in 50mL methyl alcohol by 5.0gL-tryptophan methyl ester (24.5mmol) and 6.0mL1,1,3,3-tetramethoxy propane (23.6mmol), adjust pH to 2 with hydrochloric acid (5M), 45 DEG C are stirred 48 hours.Reaction mixture is at concentrating under reduced pressure, and residue 50mL water dissolution, the solution with ethyl acetate of formation extracts (30mL × 3).The ethyl acetate solution merged, uses 10%Na successively 2cO 3the aqueous solution (3 × 30mL) and the saturated NaCl aqueous solution (2 × 30mL) are washed, and then use anhydrous Na 2sO 4drying, filter, concentrating under reduced pressure, obtains title compound, ESI-MS (m/z): 319 [M+H] +.
Embodiment 2 prepares (5aS, 12S/R, 14aS)-5,14-diketone-12-Methylal(dimethoxymethane)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine is [1,2:1,6] pyrido [3,4-b] indoles (2) also
4.3g (17.2mmol) Z-Pro is dropped in the reaction flask being connected with device for absorbing tail gas, 5ml oxalyl chloride and 2 dry DMF are dripped after dissolving with 30mL anhydrous methylene chloride, produce a large amount of bubble, react 5 hours, with acetic acid ethyl dissolution and concentrating under reduced pressure three times (5ml × 3) after compound of reaction concentrating under reduced pressure, residue ether soaks, and obtains the shallow white solid of Z-Pro-Cl, not purified, be directly used in next step reaction.
4.77g (15.0mmol) (3S)-1-(2, 2-dimethoxy ethyl)-2, 3, 4, 9-tetrahydro-beta-carboline carboxylate methyl ester 50mL anhydrous methylene chloride dissolves, ice-water bath cools, add the Z-Pro-Cl that 3.87g (14.3mmol) is just obtained, reaction solution pH9 is kept with diisopropylamine, stirring at room temperature 24 hours, TLC monitors raw material spot and disappears, pressure reducing and steaming solvent, 200mgPd/C and 1ml formic acid is added after resistates 50ml dissolve with ethanol, stirring at room temperature 12 hours, make cyclization while removing Z protecting group, TLC monitors raw material spot and disappears.Concentrating under reduced pressure, resistates silica gel column chromatography obtains 3.91g (61%) title compound.ESI-MS(m/z)：338[M+H] +。
Embodiment 3 prepares (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3a) and (5aS, 12R, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3b)
Toward 2.3g (6.8mmol) (5aS, 12S/R, 14aS)-5,14-diketone-12-Methylal-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,2.4g (6.8mmol) HClTrp-OBzl, 1.5ml triethylamine and 6g anhydrous sodium sulphate is added in the solution of 6] pyrido [3,4-b] indoles and 10 milliliters of DMF.Reaction mixture is at room temperature stirred 3 hours.The solution of 1g (18.4mmol) POTASSIUM BOROHYDRIDE and 10ml methyl alcohol in addition in reaction mixture, and stir 1 hour.By reaction mixture concentrating under reduced pressure, resistates is dissolved in 40ml ethyl acetate and 20ml deionized water.Two phase liquid 2ml hydrochloric acid (5M) process, the POTASSIUM BOROHYDRIDE of decomposing excessive, and regulate pH to 9 with ammoniacal liquor (5M).Separate ethyl acetate layer, aqueous phase is extracted with ethyl acetate (40ml × 3).The ethyl acetate merged is washed with the saturated NaCl aqueous solution of 40ml mutually, with anhydrous sodium sulfate drying, filters, concentrating under reduced pressure.Resistates column chromatography purification (CHCl 3/ CH 3oH, 30/10), obtain 1.3g (61%) 3a and 1.5g (71%) 3b.
3a：FT-MS(m/z)：615.2830[M] +；mp：175-176℃； 1HNMR(300MHz，CDCl 3)：δ＝8.223(s，1H)，7.756-7.584(dd，J＝7.5Hz，J＝7.5Hz，2H)，7.494-7.411(m，3H)，7.411(m，3H)，7.386-7.317(m，5H)，7.155-7.149(m，3H)，7.05(m，1H)，6.084-6.057(d，J＝8，1Hz，1H)，5.538-5.488(q，J＝4.8Hz，5.1Hz，1H)，5.216(s，2H)，4.174(m，1H)，4.106(m，1H)，4.004-3.988(d，J＝4.8Hz，1H)，3.559-3.542(m，1H)，3.434-3.288(td，J＝5.1Hz，J＝3.0Hz，J＝3.0Hz，2H)，2.959-2.910(m，2H)，2.886-2.757(m，2H)，2.743-2.655(m，1H)，2.466-2.376(m，1H)，2.318-2.198(m，2H)，2.098-1.913(m，2H)； 13CNMR(75MHz，CDCl 3)：δ＝173.86，169.48，165.90，165.83，156.14，136.34，135.96，135.71，135.38，133.96，133.53，129.60，128.61，128.34，128.21，126.99，126.10，125.66，123.71，122.59，122.13，121.39，120.30，120.12，120.01，119.41，118.88，118.17，117.66，115.44，112.07，111.83，111.43，111.23，106.39，105.70，66.68，62.21，59.34，59.19，58.89，57.40，56.95，50.28，49.14，46.24，45.37，44.46，40.43，35.44，29.51，28.64，28.54，23.24，23.12，21.41，21.23，10.00；IR(KBr)：3308，2978，2954，2880，1659，1454，1398，1335，1236，1096，745cm -1。
3b：FT-MS(m/z)：615.2845[M] +；mp：105-106℃； 1HNMR(300MHz，CDCl 3)：δ＝11.087(s，1H)，10.677(s，1H)，7.458-7.404(dd，J＝4.8Hz，J＝5.2Hz，2H)，7.295-7.250(m，7H)，7.075-6.935(m，4H)，6.068-6.040(dd，J＝1.8Hz，J＝1.8Hz，1H)，5.216-5.134(dt，J＝7.8Hz，J＝7.8Hz，2H)，4.765-4.734(dd，J＝2.7Hz，J＝2.4Hz，1H)，4.258-4.235(d，J＝6.9Hz，1H)，4.193-4.138(m，2H)，3.806-3.790(m，1H)，3.428-3.388(dd，J＝2.7Hz，J＝2.7Hz，2H)，3.333(m，4H)3.012-2.982(m，2H)，2.875-2.727(m，1H)，2.407-2.361(t，J＝6.9Hz，J＝6.9Hz，1H)，2.226-2.209(t，J＝2.4Hz，2.7Hz，1H)，2.176-2.124(m，1H)，1.934-1.918(m，1H)，1.855-1.788(m，2H)； 13CNMR(75MHz，CDCl 3)：δ＝174.03，165.51，164.42，136.66，136.55，136.29，135.99，133.66，128.81，128.29，127.82，127.13，126.58，121.68，121.14，119.23，118.82，118.26，118.02，111.61，111.25，106.00，105.56，66.04，58.77，53.54，52.90，46.90，46.40，45.06，29.93，28.63，25.22，21.46；IR(KBr)：3251，3233，2957，2930，2857，1659，1454，1398，1150，748cm -1。
Embodiment 4 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophane-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (CIPPC)
Under ice bath, by 1.3g (2.1mmol) (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophan benzyl ester group-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B] indoles (3a) is dissolved in 5ml methyl alcohol, and dropwise add the NaOH aqueous solution (4M) and regulate pH to 12, reaction mixture is stirred 2 hours under ice bath.With hydrochloric acid (2M), pH to 5 is adjusted in reaction, concentrating under reduced pressure, by residue over silica gel column separating purification, obtains 863mg (90%) title compound CIPPC.ESI-MS(m/z)：526[M+H] +； 1HNMR(400MHz，DMSO)，δ(ppm)＝11.27(s，1H)，10.86(s，1H)，7.54(dd，J＝7.6，J＝7.6Hz，2H)，7.33(m，2H)，7.13(s，1H)，7.06(s，2H)，6.92(t，J＝7.2Hz，1H)，5.38(s，1H)，4.50(s，1H)，4.29(m，2H)，3.45-3.34(m，4H)，3.24(s，1H)，3.15(m，2H)，2.83(m，1H)，2.51(s，1H)，2.22(s，1H)，1.98-1.79(m，5H). 13CNMR(100MHz，DMSO)，δ(ppm)＝171.11，170.44，165.55，136.34，136.00，133.98，125.95，124.11，121.65，118.64，118.47，118.19，111，71，111.47，109.49，105.53，101.53，63.10，62.17，58.69，56.32，52.87，49.42，45.03，43.18，40.37，40.16，39.95，36.27，34.60，28.21，26.75，22.93，21.33.IR(KBr)：3390.86，3269.34，3113，3057，3014，2954，2933，2877，1640，1465，1303，1130，1103，1008，762，702cm -1。
Embodiment 5 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl tryptophan benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4a)
120mg (0.23mmol) CIPPC and 77mg (0.23mmol) Trp-OBzl is dissolved in 15ml dry DMF, adds 100mg (0.46mmol) DCC and 30mg anhydrous Na 2sO 4.Reaction mixture N-methylmorpholine is adjusted pH to 9, and at room temperature stirs 1 hour.By reaction mixture at vacuum rotary steam, resistates is dissolved in 20ml ethyl acetate, by solution 10%Na 2cO 3the aqueous solution is washed (15mL × 3), and uses anhydrous Na 2sO 4dry.After filtration, filtrate is through concentrating under reduced pressure, and by residue over silica gel column purification, obtaining 148mg (80%) title compound, is pale yellow powder.Mp.122-123℃；ESI-MS(m/z)：803[M+H] +； 1HNMR(300MHz，DMSO)，δ(ppm)＝11.05(S，1H)，10.84(S，1H)，10.66(S，1H)，8.44(d，J＝7.2Hz，1H)，7.57(d，J＝10.2Hz，1H)，7.49(d，J＝17.7Hz，1H)，7.38(m，2H)，7.31(m，1H)，7.27(m，2H)，6.99(m，2H)，6.93(m，1H)，6.20(d，J＝6.9Hz，1H)，4.99(s，2H)，4.74(dd，J＝3.9Hz，J＝4.2Hz，1H)，4.65(dd，J＝7.2Hz，J＝7.2Hz，1H)，4.14(m，2H)，3.85(t，J＝5.7Hz，1H)，3.75(m，1H)，3.40(dd，J＝4.5Hz，J＝4.5Hz，1H)，3.34(m，2H)，3.26(d，J＝7.5Hz，2H)，2.94(d，J＝5.1Hz，H)，2.89(s，1H)，2.76(m，2H)，2.74(s，1H)，2.39(t，J＝12.6Hz，1H)，2.17(dd，J＝3.3Hz，J＝3.9Hz，2H)，1.78(m，3H)，1.40(s，1H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝173.41，172.18，165.60，164.54，162.76，136.68，136.55，136.51，136.26，133.91，128.73，128.33，128.14，127.66，127.36，126.66，124.05，121.61，121.48，121.12，119.20，118.91，118.76，118.46，118.24，117.94，111.94，111.61，111.31，110.07，106.94，105.67，67.49，66.39，60.19，59.03，54.01，53.82，52.51，47.24，46.75，45.04，36.23，31.26，29.89，28.70，27.56，26.82，25.60；IR(KBr)：3428，3254，2955，2928，2855，1659，1456，1422，1340，1234，842，146cm -1。
Embodiment 6 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl phenylalanine benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4b)
According to the method for embodiment 5, from 120mg (0.23mmol) CIPPC and 67mg (0.23mmol) Phe-OBzl
Obtaining 130mg (74%) title compound, is pale yellow powder.Mp.145-146℃；ESI-MS(m/z)：764[M+H] +； 1HNMR(300MHz，DMSO)，δ(ppm)＝8.32(s，1H)，7.96(m，1H)，7.46(m，4H)，7.40(m，4H)，7.25(m，5H)，7.13(m，5H)，5.98(s，1H)，5.13(m，2H)，4.98(m，1H)，4.14(dd，J＝4.2Hz，J＝4.2Hz，1H)，4.00(t，J＝7.5Hz，1H)，3.88(dd，J＝4.8Hz，J＝4.8Hz，1H)，3.58(m，2H)，3.48(dd，J＝2.4Hz，J＝2.7Hz，1H)，3.38(d，J＝4.8Hz，1H)，3.33(d，J＝5.1Hz，1H)，3.24(dd，J＝7.9Hz，J＝7.9Hz，1H)，3.07(dd，J＝7.2Hz，J＝7.2Hz，1H)，2.97(m，2H)，2.93(m，2H)，2.60(m，1H)，2.41(m，2H)，2.20(m，2H)，2.98(m，2H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝174.07，172.00，165.24，164.58，136.49，136.39，135.55，135.01，131.86，129.32，129.17，128.68，128.58，128.50，128.45，128.23，127.45，126.89，126.20，123.43，122.21，121.94，119.61，119.48，118.77，118.02，111.36，110.77，105.72，67.96，67.40，67.22，63.73，59.02，53.87，52.61，47.23，47.18，45.07，45.00，37.60，34.97，30.08，29.69，29.37，28.32，25.61，23.30，21.47，8.62；IR(KBr)：3383，3233，2978，2955，1640，1456，1406，1339，1234，1207，745，702cm -1。
Embodiment 7 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl Serine benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4c)
According to the method for embodiment 5, obtaining 123mg (76%) title compound from 120mg (0.23mmol) CIPPC and 53mg (0.23mmol) Ser-OBzl, is pale yellow powder.Mp.137-138℃；ESI-MS(m/z)：703[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝8.24(s，1H)，7.86(d，J＝7.2Hz，1H)，7.44(m，2H)，7.32(m，6H)，7.30(m，1H)，7.13(m，4H)，6.61(s，1H)，5.18(s，2H)，4.73(dt，J＝3.6Hz，J＝4.2Hz，J＝3.6Hz，1H)，4.43(m，1H)，4.03(m，2H)，3.97(m，2H)，3.44(m，2H)，3.38(m，2H)，3.22(m，2H)，3.16(m，2H)，2.96(m，2H)，2.52(m，1H)，2.38(m，2H)，2.23(m，1H)，1.99(m，2H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝175.05，170.49，170.37，165.90，136.42，135.67，135.14，133.91，128.59，128.50，128.25，12708，125.84，124.76，122.48，121.77，119.83，119.75，119.28，117.86，111.98，111.56，111.43，105.81，67.44，63.42，60.84，59.34，57.14，54.63，48.46，47.47，45.24，43.22，36.43，35.65，29.3，29.28，28.60，23.26，20.89，8.70；IR(KBr)：3358，2957，2884，1649，1456，1417，1234，1024，748cm -1。
Embodiment 8 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl tyrosine benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4d)
According to the method for embodiment 5, from 120mg (0.23mmol) CIPPC and 71mg (0.23mmol) Tyr-OBzl
Obtaining 125mg (70%) title compound, is pale yellow powder.Mp.113-114℃；ESI-MS(m/z)：780[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝7.97(s，1H)，7.86(t，J＝11.4Hz，J＝7.5Hz，2H)，7.43(t，J＝7.8Hz，2H)，7.33(m，5H)，7.29(m，2H)，7.16(d，J＝11.4Hz，2H)，7.11(m，1H)，7.03(d，J＝8.1Hz，2H)，6.85(d，J＝8.1Hz，2H)，6.63(s，1H)，5.12(dd，J＝5.1Hz，J＝5.1Hz，2H)，4.13(d，J＝7.2Hz，1H)，4.00(t，J＝8.1Hz，J＝7.5Hz，1H)，3.87(dd，J＝4.8Hz，J＝4.8Hz，1H)，3.58(m，2H)，3.37(m，1H)，3.30(d，J＝4.8Hz，1H)，3.24(d，J＝4.8Hz，1H)，2.96(s，1H)，2.89(s，1H)，2.83(m，1H)，2.74(m，1H)，2.37(m，1H)，2.19(m，3H)，2.06(m，2H)，1.97(m，1H)，1.54(m，1H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝174.66，171.42，170.68，166.02，155.88，136.36，135.62，135.20，133.75，130.36，129.56，128.59，128.51，127.00，126.87，126.80，125.73，124.71，122.14，121.72，119.67，119.58，119.41，117.77，115.58，115.39，111.70，111.46，110.97，105.52，67.21，60.14，59.33，57.08，52.20，48.15，45.25，42.63，37.58，36.53，35.03，31.91，31.47，29.68，29.34，28.85，28.60，23.27，22.67，20.68，14.09；IR(KBr)：3229，3215，2956，2887，1648，1454，1404，1296，1151，746cm -1。
Embodiment 9 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl Methionin benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4e)
According to the method for embodiment 5, obtaining 103mg (60%) title compound from 120mg (0.23mmol) CIPPC and 54mg (0.23mmol) Lys-OBzl, is pale yellow powder.Mp.113-114℃；ESI-MS(m/z)：745[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝8.42(s，1H)，7.88(d，J＝7.8Hzl，H)，7.47(m，3H)，7.32(m，12H)，7.19(m，3H)，7.14(m，1H)，5.13(m，4H)，4.96(m，1H)，4.68(m，1H)，4.32(m，1H)，3.97(t，J＝8.0Hz，H)，3.90(dd，J＝5.1Hz，J＝4.8Hz，1H)，3.62(m，2H)，3.52(m，1H)，3.47(m，1H)，3.39(dd，J＝4.5Hz，J＝4.8Hz，1H)，3.14(m，2H)，2.95(m，2H)，2.45(m，3H)，2.25(m，1H)，2.03(m，1H)，1.95(m，2H)，1.67(m，1H)，1.50(m，3H)，1.28(m，3H)，1.21(m，2H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝174.52，172.25，170.58，165.87，156.50，136.63，136.51，135.55，135.29，133.89，128.59，128.52，128.47，128.45，128.02，127.09，125.78，124.83，122.53，121.77，119.92，119.78，119.53，117.86，112.01，111.96，11.32，105.73，67.13，66.61，60.24，59.38，57.18，51.27，48.03，45.96，45.22，42.84，40.82，35.27，32.17，29.67，29.22，28.72，23.32，22.47，20.79；IR(KBr)：3373，3323，2947，2868，1650，1456，1406，1335，1234，1202，1026，746cm -1。
Embodiment 10 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl proline(Pro) benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4f)
According to the method for embodiment 5, obtaining 118mg (72%) title compound from 120mg (0.23mmol) CIPPC and 81mg (0.23mmol) Pro-OBzl, is pale yellow powder.Mp.112-113℃；ESI-MS(m/z)：714[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝10.83(s，1H)，10.72(s，1H)，7.55(d，J＝7.5Hz，1H)，7.45(d，J＝7.1Hz，1H)，7.39(m，4H)，7.24(m，3H)，7.18(d，J＝7.8Hz，1H)，7.08(m，1H)，7.02(m，2H)，6.95(m，1H)，5.08(m，2H)，4.30(m，1H)，4.28(m，1H)，4.26(m，1H)，3.62(m，2H)，3.49(m，1H)，3.09(m，2H)，2.78(m，1H)，2，74(m，1H)，2.67(m，1H)，2.35(m，1H)，2.28(m，1H)，2.22(m，1H)，2.12(m，3H)，1.95(m，2H)，1.94(m，2H)，1.86(m，1H)，1.75(m，3H)；IR(KBr)：3433，3285，2955，2882，1741，1692，1456，1406，1339，1171，821，743cm -1。
Embodiment 11 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl leucine benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4g)
According to the method for embodiment 5, obtaining 118mg (80%) title compound from 120mg (0.23mmol) CIPPC and 59mg (0.23mmol) Leu-OBzl, is pale yellow powder.Mp.127-128℃；ESI-MS(m/z)：730[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝8.20(s，1H)，8.00(d，J＝7.8Hz，1H)，7.90(d，J＝9.6Hz，1H)，7.49(m，4H)，7.36(d，J＝2.1Hz，1H)，7.33(m，5H)，7.16(m，2H)，7.06(m，1H)，5.83(s，1H)，5.13(dd，J＝12Hz，J＝4.8Hz，2H)，4.82(m，1H)，4.79(m，1H)，4.09(dd，J＝3.6Hz，J＝3.6Hz，1H)，4.02(t，J＝7.9Hz，1H)，3.92(dd，J＝5.4Hz，J＝5.1Hz，1H)，3.64(m，2H)，3.36(dd，J＝5.1Hz，J＝5.1Hz，1H)，2.85(qq，J＝11.7Hz，J＝4.2Hz，2H)，2.44(m，2H)，2.32(m，2H)，2.04(m，2H)，1.67(m，4H)，1.40(m，1H)，1.24(dd，J＝3.6Hz，J＝6.9Hz，2H)，1.11(m，1H)，0.99(s，6H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝174.49，172.91，170.77，165.90，136.57，135.50，135.38，133.84，130.90，128.85，128.54，128.41，126.96，125.73，124.95，122.65，121.77，120.00，119.78，119.72，117.83，112.30，112.08，111.32，105.64，67.05，65.57，60.04，59.41，59.12，57.22，50.14，47.66，45.42，45.22，42.56，41.47，34.93，30.59，30.02，29.69，29.35，28.76，24.94，23.36，22.99，21.71，20.68，19.19，13.72，11.03；
IR(KBr)：3397，2934，1653，1456，1398，1148，743cm -1。
Embodiment 12 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl Isoleucine benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4h)
According to the method for embodiment 5, obtaining 119mg (82%) title compound from 120mg (0.23mmol) CIPPC and 59mg (0.23mmol) Ile-OBzl, is pale yellow powder.Mp.129-130℃；ESI-MS(m/z)：730[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝8.31(s，1H)，7.99(s，1H)，7.93(s，1H)，7.44(m，4H)，7.33(s，5H)，7.28(m，2H)，7.17(m，2H)，6.93(m，1H)，5.13(dd，J＝12Hz，J＝19.8Hz，2H)，4.70(dd，J＝4.8Hz，J＝4.2Hz，1H)，4.16(s，1H)，3.97(t，J＝8.0Hz，H)，3.86(dd，J＝4.5Hz，J＝4.5Hz，1H)，3.65(m，2H)，3.56(m，2H)，3.36(dd，J＝5.4Hz，J＝4.5Hz，1H)，2.84(m，2H)，2.35(m，4H)，2.01(m，3H)，0.96(m，6H)；13C-NMR(75Hz，DMSO-d6δ(ppm)＝174.34，171.85，170.69，165.88，136.57，135.54，135.38，133.84，128.62，128.59，128.53，128.46，128.42，126.95，125.76，124.90，122.59，121.77，119.95，119.78，119.61，117.83，112.15，112.03，111.36，105.69，66.92，60.28，59.38，57.18，56.14，47.75，45.19，42.67，37.88，34.97，30.07，28.69，25.01，23.31，20.70，15.69，11.50；IR(KBr)：3367，3347，2961，2926，2874，1649，1456，1409，1234，1150，745cm -1。
Embodiment 13 prepares (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl-glycine benzyl ester-ethyl-1-base)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B]-indoles (4i)
According to the method for embodiment 5, obtaining 136mg (88%) title compound from 120mg (0.23mmol) CIPPC and 46mg (0.23mmol) Gly-OBzl, is pale yellow powder.Mp.132-133℃；ESI-MS(m/z)：674[M+H] +； 1H-NMR(300MHz，DMSO)，δ(ppm)＝8.24(s，1H)，8.10(dd，J＝9.6Hz，J＝7.2Hz，1H)，7.44(m，3H)，7.37(m，1H)，7.32(m，5H)，7.28(m，3H)，7.11(d，J＝3.9Hz，1H)，7.08(m，1H)，6.12(s，1H)，5.17(s，2H)，4.72(dd，J＝2.4Hz，J＝4.0Hz，1H)，4.47(m，1H)，4.23(dd，J＝4.2Hz，J＝4.5Hz，1H)，4.01(t，J＝8.7Hz，H)，3.90(dd，J＝4.8Hz，J＝5.1Hz，1H)，3.65(m，2H)，3.56(m，1H)，3.49(m，1H)，3.37(dd，J＝5.1Hz，J＝5.1Hz，1H)，3.16(q，J＝7.5Hz，1H)，2.87(m，2H)，2.40(m，2H)，2.30(m，1H)，2.04(m，3H)； 13C-NMR(75Hz，DMSO-d6δ(ppm)＝175.09，170.61，169.86，165.91，136.55，135.53，135.24，133.80，128.62，128.52，128.42，127.03，125.77，125.00，122.53，121.81，119.90，119.81，119.52，117.86，112.01，111.93，111.34，105.72，67.14，65.83，60.29，59.32，57.09，47.92，45.21，42.99，40.93，35.28，29.74，28.68，23.28，20.74，15.25；IR(KBr)：3397，2959，2926，2855，1649，1456，1412，1207，1146，748cm -1。
Experimental example 1 assessing compound 4a-j is to the restraining effect of tumor cell proliferation
1) substratum of compound 4a-j of the present invention containing 0.1%DMSO is mixed with desired concn.
2) tumour cell of experiment is HL60 and HT-29.
3) cultivate and MTT with 96 hole microtiter plates, [(3-4,5-dimethylthiazole-2-base)-2,5-phenylbenzene nitrogen azoles bromine salt] Thiazolyl blue dyeing, operates according to standard program.HL60 and HT-29 cell (5 × 10 4individual cells/well) be incubated at RPMI-1640 or DMEM substratum (containing 10%, v/v) foetal calf serum, 60 μ g/ml penicillin, and 100 μ g/ml Streptomycin sulphates.The DMSO solution substratum of CIPPCT is diluted to desired concn.Cell in 37 DEG C of incubators (containing 5%CO 2) cultivate 24 hours, then add the CIPPCT solution that final concentration is respectively 0,1,5,10,25,50 and 100 μM.Cultivate after 48 hours, add MTT solution (5 μ g/ml, 25 μ l/ holes), and cell is cultivated 4 hours again.Add 100 μ lDMSO, after dissolving MTT-first a ceremonial jade-ladle, used in libation product, measure the absorption value (O.D., n=6) at 570nm place by microplate reader.
The activity of compound 5 inhibition tumor cell propagation under each concentration is obtained by following formula:
Cell proliferation (%)=(the average O.D. value of CIPPC-AA-OBzl group average O.D. value/blank group) × 100%, experiment repetition 6 times, maps to drug level with cell proliferation, obtains IC by graphing method 50(half effective inhibition concentration) value.
4) the results are shown in Table 1.Result shows that compound 4a-k has obvious restraining effect to HL60 and HT-29 cell proliferation.
Table 1. compound 4a-j is on the impact (IC of HL60 and HT-29 cell proliferation 50, mean value ± SD μM)
Experimental example 2 assessing compound 4a-j is to the restraining effect of tumor growth
1) the compound 4a-j 0.3%CMC-Na aqueous solution of the present invention suspends, and Zorubicin physiological saline solution is as positive control, and the 0.3%CMC-Na aqueous solution makes negative control;
2) the 0.3%CMC-Na suspension of compound 4a-j and the equal gastric infusion of the 0.3%CMC-Na aqueous solution, the dosage of CIPPCT is the dosage of 4 μm of ol/kg, 0.3%CMC-Na aqueous solution is 0.2ml/20g, successive administration 7 days, altogether administration 7 times; Zorubicin abdominal injection, dosage is 2 μm of ol/kg, successive administration 7 days, altogether administration 7 times.
3) laboratory animal is ICR male mice (cleaning grade), body weight 20 ± 2g, often organizes 7 mouse.
4) knurl source is mouse S 180 sarcoma, purchased from Department Of Medicine, Peking University's animal experimental center, and maintenance of going down to posterity voluntarily.
5) extract and inoculate eugonic S180 ascitic tumor knurl liquid under animal model and treatment aseptic condition, the liquid of (1: 2) is become fully to mix with normal saline dilution, by freshly prepared 0.2% Trypan Blue of tumor cell suspension, by white blood cell count(WBC) method counting after mixing, contaminate blue person for dead cell, tinter is not viable cell, and is calculated as follows cell concn and cell survival rate.
Viable count/4 × 10 in the block plaid of cell concn=4 4× extension rate=cell count/ml
Cell survival rate=viable count/(viable count+dead cell number) × 100%
Knurl liquid homogenate method survival rate being greater than 90% is prepared into 2.0 × 10 7the cell suspension of individual/ml, in the subcutaneous vaccination of mouse armpit, 0.2ml/ only, manufactures S180 tumor-bearing mice.After tumor inoculation 24h, the 0.3%CMC-Na suspension for the treatment of group mouse oral CIPPCT every day, dosage is 4,0.8 and 0.16 μm of ol/kg.Naive mice oral 0.2ml0.3%CMC-Na aqueous solution every day.Positive controls mouse abdominal injection every day Zorubicin, dosage is 2 μm of ol/kg.Experiment proceeds to the 7th day, claim Mouse Weight, etherization, de-cervical vertebra puts to death mouse, then fixes the right armpit tumor location of mouse with tweezers, cuts off skin, expose tumour, blunt separation, weighs, and is calculated as follows tumour inhibiting rate: tumour inhibiting rate %=(heavy-AIPPCT of the average knurl of 0.3%CMC-Na aqueous solution group organizes average knurl weight) the average knurl of/0.3%CMC-Na aqueous solution group heavy × 100%.Experimental data adopts t inspection and variance analysis, knurl heavy with ( ) represent.The results are shown in Table 2.As can be seen from Table 2, under the oral dosage of 4 μm of ol/kg, except compound 4h, outside i, in compound 4a-j, the knurl of all the other compounds for treating mouse weighs tool significant difference compared with 0.3%CMC-Na aqueous solution group, illustrates that they have definite anti-tumor activity.In addition, the effective dose of compound 4b, j is low reaches 0.8 μm of ol/kg.Visible, by AA-OBzl, (AA is selected from L-Trp, L-Phe, L-Ser, L-Tyr, Lys (Z), L-Pro, L-Leu, L-Ile, L-Val and Gly residue) guide on the carboxyl of the tryptophan residue of CIPPC, can effectively be suppressed by CIPPC the anastalsis of urokinase plasmin activity to be converted into antitumor action.
The impact (mean value ± SDg) that table 2. compound 4a-j is heavy on S180 mouse tumor
Compound (dosage μm ol/kg) Knurl weight Compound (dosage μm ol/kg) Knurl weight
Zorubicin (2) 0.91±0.42 a CMC-Na 1.55±0.48
Compound 4a (4) 0.97±0.41 a Compound 4f (4) 1.22±0.52 b
Compound 4b (0.8) 1.05±0.27 a Compound 4g (4) 1.20±0.39 b
Compound 4c (4) 1.07±0.46 b Compound 4h (4) 1.25±0.39
Compound 4d (4) 1.04±0.35 a Compound 4i (4) 1.60+0.38
Compound 4e (4) 1.08±0.31 a Compound 4j (0.8) 1.13±0.37 b
N=10; A) P < 0.01 is compared with CMC-Na group; B) P < 0.05. is compared with CMC-Na group
Experimental example 4 measures the transmission electron microscope photo of compound 4a-j
By compound 4a-j according to 1 × 10 -10the concentration configuration pure water solution of M, is layered on uniformly on copper mesh, observes the self-assembly property of compound under transmission electron microscope (TEM, JEM-1230, JEOL).The photo obtained is as Fig. 2.Result shows, compound 4a-j can form nano particle in water, and diameter is 50-200nm.

Claims (4)

1. (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1 of below structure, 2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5]-pyrazine also [1,2:1,6] pyrido [3,4-b] indoles
AA is selected from L-Trp, L-Phe, L-Ser, L-Tyr, Lys (Z), L-Pro, L-Leu, L-Ile, L-Val and Gly residue.
2. (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1 of claim 1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5]-pyrazine also [1,2:1,6] preparation method of pyrido [3,4-b] indoles, the method is made up of following steps:
(1) in presence of hydrochloric acid, L-Trp methyl esters and the condensation of 1,1,3,3-tetramethoxy propane are 1-(2,2-dimethoxy-ethyl)-1,2,3,4-Tetrahydrocarboline-3-carboxylate methyl ester;
(2) 1-(2,2-dimethoxy-ethyl)-1,2,3 under diisopropylamine exists, 4-Tetrahydrocarboline-3-carboxylate methyl ester and Z-Pro-Cl condensation are (5aS, 12S/R, 14aS)-5,14-diketone-12-Methylal(dimethoxymethane)-1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles [1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-b] indoles (2);
(3) under the existence of triethylamine and anhydrous sodium sulphate, (5aS, 12S/R, 14aS)-5, 14-diketone-12-Methylal(dimethoxymethane)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles [1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-b] indoles (2) and HClTrp-OBzl condensation be (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-N-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3a) and (5aS, 12R, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-N-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3b),
(4) under ice bath in methyl alcohol (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophan benzyl ester group-N-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (3a) hydrolysis generation (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophane ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (CIPPC),
(5) under ice bath in dry DMF, by N, N-dicyclohexylcarbodiimide (DCC) and anhydrous Na 2sO 4make dewatering agent.(5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophane ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (CIPPC) and AA-OBzl N-methylmorpholine reconcile pH to 9, at room temperature coupling generates (5aS, 12S, 14aS)-5, 14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1, 2, 3, 5, 5a, 6, 11, 12, 14, 14a-decahydro-5H, 14H-pyrroles-[1, 2:4, 5] pyrazine also [1, 2:1, 6] pyrido [3, 4-B] indoles (CIPPC-AA-OBzl).
3. (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1 of claim 1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] nanostructure of pyrido [3,4-B] indoles.
4. (5aS, 12S, 14aS)-5,14-diketone-12-(2-tryptophyl amino-acid benzyl ester group-ethyl-1-base)-1 of claim 1,2,3,5,5a, 6,11,12,14,14a-decahydro-5H, 14H-pyrroles-[1,2:4,5] pyrazine also [1,2:1,6] pyrido [3,4-B] indoles is preparing the application in antitumor drug.
CN201410312102.7A 2014-07-03 2014-07-03 CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof Pending CN105315332A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410312102.7A CN105315332A (en) 2014-07-03 2014-07-03 CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410312102.7A CN105315332A (en) 2014-07-03 2014-07-03 CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof

Publications (1)

Publication Number Publication Date
CN105315332A true CN105315332A (en) 2016-02-10

Family

ID=55243722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410312102.7A Pending CN105315332A (en) 2014-07-03 2014-07-03 CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof

Country Status (1)

Country Link
CN (1) CN105315332A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107502623A (en) * 2016-06-13 2017-12-22 首都医科大学 VEGF siRNA Nano diamond is delivered, it is prepared, activity and application
CN108976159A (en) * 2017-05-30 2018-12-11 首都医科大学 The indoles alcohol derivative of ArAA modification, synthesis, activity and application
CN109081801A (en) * 2017-06-13 2018-12-25 首都医科大学 The indoles alcohol derivative of acidic amino acid modification, synthesis, activity and application
CN109081802A (en) * 2017-06-13 2018-12-25 首都医科大学 The indoles alcohol derivative of basic amino acid modification, synthesis, activity and application
CN109081803A (en) * 2017-06-13 2018-12-25 首都医科大学 The indoles alcohol derivative of polar amino acid modification, synthesis, activity and application
CN109111390A (en) * 2017-06-23 2019-01-01 首都医科大学 The indoles alcohol derivative of Met modification, synthesis, activity and application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FENGXIANG DU等: "Mechanism of forming trimer, self-assembling nano-particle and inhibiting tumor growth of small molecule CIPPCT", 《MED. CHEM. COMMUN.》 *
JIANHUI WU等: "A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
JIAWANG LIU等: "Pyrolo[1,2:4,5]-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indoles: A Group of Urokinase Inhibitors, their Synthesis,and Stereochemistry-Dependent Activity", 《CHEM MED CHEM》 *
XIAOYI ZHANG等: "A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107502623A (en) * 2016-06-13 2017-12-22 首都医科大学 VEGF siRNA Nano diamond is delivered, it is prepared, activity and application
CN107502623B (en) * 2016-06-13 2021-06-08 首都医科大学 Nanodiamonds delivering VEGF-siRNA, their preparation, activity and use
CN108976159A (en) * 2017-05-30 2018-12-11 首都医科大学 The indoles alcohol derivative of ArAA modification, synthesis, activity and application
CN108976159B (en) * 2017-05-30 2020-07-28 首都医科大学 Aromatic amino acid modified indole ethanol derivative, and synthesis, activity and application thereof
CN109081801A (en) * 2017-06-13 2018-12-25 首都医科大学 The indoles alcohol derivative of acidic amino acid modification, synthesis, activity and application
CN109081802A (en) * 2017-06-13 2018-12-25 首都医科大学 The indoles alcohol derivative of basic amino acid modification, synthesis, activity and application
CN109081803A (en) * 2017-06-13 2018-12-25 首都医科大学 The indoles alcohol derivative of polar amino acid modification, synthesis, activity and application
CN109081802B (en) * 2017-06-13 2021-03-30 首都医科大学 Indole ethanol derivative modified by basic amino acid, and synthesis, activity and application thereof
CN109081803B (en) * 2017-06-13 2021-03-30 首都医科大学 Polar amino acid modified indoloethanol derivative, and synthesis, activity and application thereof
CN109081801B (en) * 2017-06-13 2021-03-30 首都医科大学 Acidic amino acid modified indoloethanol derivative, and synthesis, activity and application thereof
CN109111390A (en) * 2017-06-23 2019-01-01 首都医科大学 The indoles alcohol derivative of Met modification, synthesis, activity and application
CN109111390B (en) * 2017-06-23 2021-03-30 首都医科大学 Met-modified indoloethanol derivative, and synthesis, activity and application thereof

Similar Documents

Publication Publication Date Title
CN105315332A (en) CIPPC-AA-OBzl, and preparation, nano structure, activity and application thereof
CN103450199B (en) Theanine modify carboline acyl aminoacid benzyl ester, its preparation, anti-tumor activity and application
CN102250202B (en) 1-paranitrophenyl-beta-carboline-3-formyl amine acid carbamates and synthesis method and use thereof
CN102127142B (en) Ilicis routundae cortex derivants and application thereof in preparing medicament capable of resisting tumors
CN103450329A (en) 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters and their synthesis, anti-tumor activity and use
CN103159828A (en) 1-(4-hydroxy-3-methoxycarbonyl)-beta-carboline-3-formyl tryptophyl amino acid benzyl ester, and synthesis and application thereof
CN109912587B (en) Side chain protection amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof
CN111848544B (en) Amino acid derivative capable of being traced by fluorescence and preparation method and application thereof
CN107986951A (en) New Topological isomerase I inhibitor and its pharmaceutical composition and its preparation method and application
CN105218634A (en) The indoles quinolizine that YIGSR modifies, its preparation, nanostructure, active and application
CN105218637A (en) The indoles quinolizine that LPNISKP modifies, its preparation, nanostructure, active and application
CN104151391B (en) A kind of oleanolic acid derivate with antitumor action and its production and use
CN104211759B (en) The formamido group acid derivative of dimethoxy hydroxyphenyl β carbolines 3, it is prepared, nanostructured, activity and application
CN105960399B (en) Enzyme inhibitor epoxy ketone compound
CN105859823A (en) Application of ilicis routundae cortex acid ester derivatives in preparation of anti-tumor drugs
CN105566398B (en) A kind of oxide of high activity aporphine alkali rhodium (III) complex and its synthetic method and application
CN101597289A (en) 2-tryptophyl-beta-tetrahydro carboline-3-formyol amino-acid benzyl ester and its production and application
CN115466316A (en) Migration-inhibiting 1-imidazole-beta-carboline-3-formyl-RGDF, preparation, anti-cancer metastasis effect and application
CN105273049A (en) CIPPCT, preparation method thereof, nanostructure thereof, activity thereof and application thereof
CN105481944B (en) A kind of two peptide copper complex of benzimidizole derivatives and its preparation method and application
CN108929320A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- oxazolidone modification, synthesis, activity and application
CN105315341A (en) [Beta]-carboline modified by Trp-Trp-Trp hexapeptide, and preparation, nano structure, activity and application thereof
CN113041361B (en) Diagnosis and treatment integrated material responding to HDAC and CTSL and preparation method and application thereof
CN105294825A (en) Nanostructure of 1-(ethyl amino acid benzyl ester)-beta-carboline-3-carboxyilc acid benzyl ester, preparation, activity and application
CN105273044A (en) 1-(ethylamino acid benzyl ester)-beta-carboline-3-benzyl carboxylate, preparation, nano-structure, activity and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160210

WD01 Invention patent application deemed withdrawn after publication